Changes in microbial signatures of the lungs and airways are associated with worsening chronic respiratory disease and persistent inflammation.
Alveolus Bio has used over a decade of pulmonary microbiome research and clinical data to inform development of novel inhaled live biotherapeutics that address airway dysbiosis and neutrophilic inflammation.
Alveolus Bio’s microbiome-based therapeutic pipeline includes active programs for Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF), Bronchopulmonary Dysplasia (BPD).
Proprietary resMIT® Delivery System
Respiratory Microbiota-based Inhaled Therapeutics
- Proprietary engineered dry powder particles are delivered by commercially available dry powder inhaler (DPI) to distal lung alveoli
- Inhaled formulations to lower dosage for safe, targeted delivery with minimal systemic side effects while maintaining efficacy
Small Molecule Programs
Alveolus Bio also has preclinical programs for Pulmonary Arterial Hypertension (PAH) and Acute Respiratory Distress Syndrome (ARDS).